BOSTON (TheStreet) -- Investors, get ready for a very busy week of biotech and pharmaceutical earnings and FDA drug decision approvals.
Monday, July 23
InterMune (ITMN) will announce second-quarter financial results before the opening bell. Investors will be focused on sales of Esbriet, which InterMune is selling in Europe as a treatment for the serious lung disease idiopathic pulmonary fibrosis. The consensus sales estimate for Esbriet in the June quarter is $7.8 million.
Also watch for what InterMune says about new patient starts on Esbriet in the quarter. First quarter new-patient adds dipped to 363 in the first quarter from 402 in the fourth quarter 2011. Given the new, more favorable reimbursement opinion in Germany, new patients on Esbriet should have rebounded and started to grow again in the June quarter.InterMune is expected to lose 28 cents a share on total revenue of $36.35 million in the second quarter. Amylin Pharmaceuticals (AMLN) and Human Genome Sciences (HGSI) also report second-quarter results on Monday but are less important given the in-process acquisitions by Bristol-Myers Squibb (BMY) and GlaxoSmithKline (GSK), respectively. Tuesday, July 24 Biogen Idec (BIIB) earnings on tap, with current consensus pegged at earnings of $1.56 per share on total revenue of $1.33 billion for the June quarter. Drilling deeper in Biogen June earnings, worldwide sales of the multiple sclerosis drug Tysabri are expected to total $415 million, with between 140 to 150 new patients starts per week in the quarter. Consensus sales estimate for Avonex, the company's other multiple sclerosis drug, is $428 million in the U.S. and $269 million ex-U.S. Questcor Pharmaceuticals (QCOR) reports second-quarter earnings, with analysts on average expected 63 cents per share on total revenue of $108.9 million. Wednesday, July 25 When Alexion Pharmaceuticals (ALXN) reports June quarter results, look for earnings of 37 cents per share on total revenue (Soliris sales) of $263 million. Regeneron Pharmaceuticals (REGN) second-quarter earnings: Consensus 25 cents per share on $255.9 million. Also reporting Wednesday are Bristol-Myers Squibb, Eli Lilly (LLY) and GlaxoSmithKline. Thursday July 26 The biggest day of the week, headlined by two FDA drug approval decisions: marin's (AMRN) prescription fish-oil pill Vascepa and Horizon Pharmaceutical's (HZNP) Lodotra, a long-acting formulation of the common steroid prednisone intended for rheumatoid arthritis pain relief.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV